Brief: Viracta Says European Commission Grants Orphan Drug Designation For Nana-val For Treatment Of Peripheral T-Cell Lymphoma
07/09/2022 14:25
Sept 7 (Reuters) - Viracta Therapeutics Inc VIRX.O :
* VIRACTA THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED
BY EUROPEAN COMMISSION FOR NANA-VAL FOR TREATMENT OF PERIPHERAL
T-CELL LYMPHOMA
Source text for Eikon: ID:nPn7DT0wHa
Further company coverage: VIRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viracta Therapeutics
See all newsBrief: Viracta Therapeutics Announces Wind Down Of Operations
Brief: Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives
Brief: Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Viracta Therapeutics Reports Q3 2024 Financial Results And Provides Business Update